CVMichael Henke - International Medical Services

MICHAEL HENKE, MD PHD
office
private
Klinik fuer Strahlenheilkunde, Radiologische Universitaetsklinik
Robert-Koch-Strasse 3 D-79106 Freiburg i.Br. - Germany
Tel (Fax): 0761/270-95500 (94970); [email protected]
Auf der Haid 65, D-79114 Freiburg i.Br. - Germany; 0761/493769
CURRENT APPOINTMENTS
Senior Consultant, Associate Professor and Head of Clinical Research Section,
Dep. for Radiation Oncology, University Clinic Freiburg
PREVIOUS APPOINTMENTS / TRAINING
1978
1979
1980
1982
1984
1991
1992
2004
Postdoctoral-fellow, Institute for Pathology, University Würzburg
Postdoctoral-fellow, Clinic for Radiation Oncology and Nuclear Medicine,
University Zürich
Postdoctoral-fellow, Dep. Cardiology, Pulmonology and Nephrology, Medical
University Clinic, Tübingen
Clinical fellow and Senior Research Scientist, Bone marrow Transplantation
Unit, City of Hope Medical Center, Duarte, California
Staff member, Dep. Hematology/Medical Oncology, Medical University Clinic,
Freiburg
Staff member – supervising physician, Krankenhaus der Barmherzigen Brüder,
Trier
Staff member – supervising physician, Dep. for Radiation Oncology,
Radiological University Clinic, Freiburg
Section head, Dep. for Radiation Oncology, Radiological University Clinic,
Freiburg
EDUCATION
1978
1989
1989
1991
1995
2001
2005
MD; PhD-Thesis, Faculty of Medicine, Freiburg University; license to practice
medicine, Reg. Präsidium Stuttgart
Board certificate: Internal Medicine
Board certificate: Hematology/Medical Oncology
Board certificate: Rheumatology
Board certificate: Radiation Oncology
Habilitation / venia legendi „Radiooncology und Radiation Treatment“, Faculty
of Medicine, Freiburg University
Associate Professor
TEACHING EXPERIENCE
1978 –1979
Histopathology Seminar for Medical Students
Michael Henke CV
1979 –1980
1980 - 1982
1985 –1988
1991
1992 –
1992 –
1996 –
1998 –
2
Nuclear Medizin and Radiotherapy Course for Medical Students
Physical Examination Course for Medical Students
Hematology Seminar for Medical Students
Diagnosis and Treatment of Rheumatologic Disease- Seminar for Residents
Internal Medicine/ Medical Oncology Lecture for Medical Students
Introduction to Radiation Oncology Lecture for Medical Students
Diagnosis and Treatment in Oncology- bed side teaching for Residents
Radiation Oncology for Localized Cancer Lecture for Medical Students
SCIENTIFIC FOCUS
- Phase II/III (registration-relevant) trials (pharmacological modification of
radiosensitivity/protection).
- Phase I/II bench to bedside studies (targeted changes of signal transduction in combination with
radiation).
- Bed to bench research (mechanisms of clinical observations; radiosenzitation/protection)
- Head&neck cancer / lung cancer / GI cancer / multimodal treatment.
AWARDS
2004
2004
ARO Study Award for outstanding clinical research
Eleonore and Fritz Hodeige Award for innovative clinical research
MEMBERSHIPS
Bund Deutscher Internisten (BDI)
Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO)
Arbeitsgemeinschaft Knochenmarktransplantation
Deutsche Gesellschaft für Radioonkologie (DEGRO)
European Society for Therapeutic Radiology and Oncology (ESTRO)
REVIEWER FOR
Lancet
Nature
Journal of the National Cancer Institute
Radiotherapy and Oncology
Strahlentherapie&Onkologie
Annals of Hematology
Clinical Cancer Research
Onkologie
Respiratory Medicine
Neoplasia
Michael Henke CV
3
CONSULTANT FOR
Roche Pharma; Johnson&Johnson/Orthobiotech; Amgen; Lilly Pharma
COOPERATIONS
- National and international clinical study groups in radiation oncolgy (see funding and
publications below)
- Dep. of Hematology, Fred Hutchinson Cancer Research Center; Seattle
- Department of Radiation Oncology, David Geffen School of Medicine at UCLA
Los Angeles
- Gesellschaft für Strahlenforschung, München
- Center for Clinical Research and Center for Clinical Studies (University Freiburg)
- Dep. Diagnostic Radiology, Freiburg Radiological University Clinic, Dep. Hemato/Oncology,
Freiburg Medical University Clinic; Freiburg University Clinic for Head&Neck Disease, Dep.
Thoraxic Oncology, Freiburg Surgical University Clinic, Dep. Abdominal Surgery, Freiburg
Surgical University Clinic
- Institute for Pathology, University Freiburg
MANAGEMENT
1984 - today head of clinical & research teams covering responsibilities for clinical & scientific
conduct, personnel and budget
1986 - 1988 responsible for clinical conduct an structural establishment of the Freiburg „bone
marrow transplantation program“, including personnel and budget
1991 – today supervising physician
2001 – 2004 vice chair of department
1995 – today head of clinical research group (since 2004 section) with responsibilities for
clinical & scientific conduct, structural development, personnel and budget
Michael Henke CV
FUNDING / CLINICAL STUDIES
German Research Foundation/ Cancer Society
1982 - 1984
Antigranulocytic Antibodies; DFG He 1286/1-1 and 2
1986 – 1989
Oncogeneproducts; DFG He 1286/2-1/2
1989
Autologous Bone Marrow Transplantation; Deutsche Krebshilfe M 31/87/
He1
Intramural
1993 – 1994
Nitric Oxide in Human Cancer Cells
1994 – 1996
Oxygenation and Radiosensitivity of Human Cancer
Industrial
1994 – 1996
Erythropoietin for Anemic Patients undergoing Radiation Treatment – Phase
II/III Feasibility Study; Cilag
1997 – 1998
Phase-II Randomized Study Investigating Safety, Feasibility and Efficacy of
Metoclopramide as Radiosensitizer for Non Small Cell Lung Cancer;
Oxygene
1997 – 2001
Randomized, Doubleblind, Multicenter Study to Investigate the Effect of 7-9
Weeks Epoetin-beta Treatment on Locoregional Tumorcontrol of Head and
Neck Cancer Patients (ARO-98-2); Boehringer/Roche
1997 – 1998
Randomized phase-III trial of radiation-therapy +/- amifo-stine in patients
with head and neck cancer (WR-38); USB
1998 – 2000
Clinical study phase-II to investigate the effect of "RP-971ST" on
prophylaxis of skin damage due to radiotherapy (RP-970015)); Regenold
2000 - 2006
Phase-I Study: Radiochemotherap (XRT, Cisplatin and Gemcitabine) for
Patients with Non Small Cell Lung Cancer, III A/B; Lilly
2001 –2006
Multinational, multicenter, double blind, placebo-con-trolled, randomized,
phase- III clinical trial to determine the efficacy and safety of IB-367 Rinse
in reducing the severity of oral mucositis in patients receiving radiotherapy
for head and neck malignancy; Intrabiotics Pharma
2001 – 2002
Phase-3 randomized, open-label comparative study of standard whole brain
radiation therapy with or without "RSR 13" in patients with brain metastases
(RSR13 RT-009); Allos
2003 – 2005
Phase-III randomized trial of concomitant radiation, cisplatin, and
tirapazamine (SR259075) versus concomitant radiation and cisplatin in
patients with advanced head and neck cancer (EFC 4690); Sanofi
2002 - 2004
Phase-IV Study on Efficacy and Compliance of Zometa in Patients
undergoing Radiation for advanced osteolytic bone metastases. (ZOL-RTX1); Novartis
4
Michael Henke CV
2002 – 2005
Phase-II Study: oral Vinorelbin and Cisplatin as Inductiontherapy and
Concommittant to Radiotherapy for limited Non Small Cell Lung Cancer;
Pierre Fabre
2005 - 2007
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate
the Efficacy and Safety of Weekly Doses of Palifermin (Recombinant
Human Keratinocyte Growth Factor, rHuKGF) for the Reduction of Oral
Mucositis in Subjects With Advanced Head and Neck Cancer Receiving
Adjuvant Radiotherapy and Chemotherapy (RT/CT); Amgen; 20020118
2005 - 2006
Phase III randomized trial of concomitant radiation, cisplatin and
tirapazamine (SR 259075) versus concomitant radiation and cisplatin in
patients with advanced head and neck cancer (EFC 5512); Sanofi
2005 - 2007
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate
the Efficacy and Safety of Weekly Doses of Palifermin (Recombinant
Human Keratinocyte Growth Factor, rHuKGF) for the Reduction of Oral
Mucositis in Subjects with Advanced Head and Neck Cancer Receiving
Radiotherapy with Concurrent Chemotherapy (RT/CT) Amgen; 20020402
2008 - 2009
A Phase 3, Randomized Trial of Chemoradiation with or without
Panitumumab in Subjects with Unresected. Locally Advanced Squamous
Cell Carcinoma of the Head and Neck (Amgen 20062080)
2009 - 2009
A randomized, double-blind, parallel group phase III clinical study to assess
the efficacy and safety of soluble beta-1,3/1,6-glucan (SBG) on oral
mucostitis in head and neck cancer patients undergoing radiation therapy
with or without chemotherapy
2009-2010
A Phase 3, randomized trial of chemoradiation with 5-Fluorouracil plus
Oxaliplatin compared with a preoperativen chemoradiation with 5Fluorouracil (local advanced Rectumcancer UICC-Stadium II /III )
2009-2011
Multicenter, open-label phase II trial on post-surgery chemoradiation in
bombination with cetuximab in squamous cell carcinoma or the head and
neck with high risk of loco regional recurrence (ACCRA-HN-Studie)
SELECTED PUBLICATIONS
5
Michael Henke CV
6
Rischin D, Peters L, O´Sullivan B, Giralt J, Yuen K, Trotti A, Bernier J, Bourhis J, Henke M,
Fisher R: Phase III study of tirapazamine, cisplatin, and radiation versus cisplatin and radiation
for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a
phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol, 2010, 28 (18):
2989-2995.
Momm F, Kaden M, Tannock I, Schumacher M, Hasse J, Henke M: Dose escalation of
gemcitabine concomitant with radiation and cisplatin for nonsmall cell lung cancer: a phase 1-2
study. Cancer, 2010; 116 (20): 4833-4839.
Miller CP, Lowe KA, Valliant-Saunders K, Kaiser JF, Mattern D, Urban N, Henke M, Blau CA:
Evaluating Erythropoietin-Associated Tumor Progression Using Archival Tissues from a Phase
III Clinical Trial. Stem Cells. 2009; 27(9):2353-61 .
Bauer VL, Braselmann H, Henke M, Mattern D, Walch A, Unger K, Baudis M, Lassmann S,
Huber R, Wienberg J, Werner M, Zitzelsberger HF: Chromosomal changes characterize head
and neck cancer with poor prognosis. J Mol Med. 2008; 86(12):1353-65.
Krzakowski M, Provencio M, Utracka-Hutka B, Villa E, Codes M, Kuten A, Henke M, Lopez
M, Bell D, Biti G, Merimsky O, Beorchia A, Riggi M, Caux NR, Pouget JC, Dubray B, David
P: Oral vinorelbine and cisplatin as induction chemotherapy and concomitant chemoradiotherapy in stage III non-small cell lung cancer: final results of an international phase II
trial. J Thorac Oncol. 2008; 3(9):994-1002.
Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, Barnato SE,
Elverman KM, Courtney DM, McKoy JM, Edwards BJ, Tigue CC, Raisch DW, Yarnold PR,
Dorr DA, Kuzel TM, Tallman MS, Trifilio SM, West DP, Lai SY, Henke M: Venous
thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin
administration for the treatment of cancer-associated anemia. JAMA 2008 299:914-24.
Rischke HC, Momm F, Henke M, Wiech T, Frommhold H: Does radiation prevent 5fluorouracil-induced colitis in the early phase of radiochemotherapy? A case report and
literature review. Strahlenther Onkol. 2007; 183(8):459-63.
Ghanem N, Lerche A, Lohrmann C, Altehoefer C, Henke M, Langer M: Quantitative and
semiquantitative evaluation of erythropoietin-induced bone marrow signal changes in lumbar
spine MRI in patients with tumor anemia. Onkologie. 2007; 30(6):303-8.
Henke M., Mattern D., Pepe M., Bézay C., Weissenberger C., Werner M., Pajonk F.: Do
Erythropoietin Receptors On Cancer Cells Explain Unexpected Clinical Findings? J Clin Oncol
2006; 24(29): 4708–13.
Henke M., Verma A., Acs G.: Erythropoietin receptors on cancer cells: exciting perspectives,
difficult to appreciate. Blood 2006; 108(3): 1107-9.
Momm F, Schafer O, Henke M.: Metastatic breast cancer causing gas gangrene.
J Pain Symptom Manage. 2006; 31(5):385
Becker G, Momm F, Xander C, Bartelt S, Zander-Heinz A, Budischewski K, Domin C, Henke
M, Adamietz IA, Frommhold H.: Religious belief as a coping strategy: an explorative trial in
patients irradiated for head-and-neck cancer. Strahlenther Onkol. 2006;182(5):270-6.
Weissenberger C, Geissler M, Otto F, Barke A, Henne K, von Plehn G, Rein A, Muller C,
Bartelt S, Henke M.: Anemia and long-term outcome in adjuvant and neoadjuvant
radiochemotherapy of stage II and III rectal adenocarcinoma: the Freiburg experience (19892002). World J Gastroenterol. 2006; 12(12):1849-58.
Wasserman TH, Brizel DM, Henke M, Monnier A, Eschwege F, Sauer R, Strnad V.: Influence of
Michael Henke CV
7
intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for headand- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial. Int J Radiat
Oncol Biol Phys. 2005; 63(4): 985-90.
Henke M.: Erythropoietin in the treatment of cancer. Onkologie. 2005; 4:181-2
Pajonk, F., Weil, A., Sommer, A., Suwinski, R., Henke, M.: The erythropoietin-receptor pathway
modulates survival of cancer cells. Oncogene. 2004; 23(55): 8987-91
Trotti, A., Garden, A., Warde, P., Symonds, P., Langer, C., Redman, R., Pajak, T.F., Fleming,
T.R., Henke, M., Bourhis, J., Rosenthal, D.I., Junor, E., Cmelak, A., Sheehan, F., Pulliam. J.,
Devitt-Risse, P., Fuchs, H., Chambers, M., O'Sullivan, B., Ang, K.K.: A multinational,
randomized phase III trial of iseganan hcl oral solution for reducing the severity of oral
mucositis in patients receiving radiotherapy for head-and-neck-malignancy. Int J Radiat Oncol,
2004; 58 (3) : 674-681
Schipper, J., Henke, M.: Erythropoietin in patients with head and neck carcinomas? Laryngo
Rhino Otol, 2004; 83 (5) : 292-297
Henke, M.: Erythropoietin and Curative Cancer Treatment. The American Journal of Oncology
Review, 2004; 3 (4) : 190-192
Fritzsche, K., Liptai, C., Henke, M.: Psychosocial distress and need for psychotherapeutic
treatment in cancer patients undergoing radiotherapy Radiother Oncol, 2004; 72: 183-189
Brink, I., Schumacher, T., Mix, M., Ruhland, S., Stoelben, E., Digel, W., Henke, M., Ghanem,
N., Moser, E., Nitzsche, E.U.: Impact of [(18)F] FDG-PET on the primary staging of small-cell
lung cancer Eur J Nucl Med Mol I, 2004
Henke, M., Sindlinger, F., Ikenberg, H., Gerds, T., Schumacher, M.: Blood hemoglobin level and
treatment outcome of early breast cancer. Strahlenther Onkol, 180:45-51, 2004
Trotti, A., Garden, A., Warde, P., Symonds, P., Langer, C., Redman, R., Pajak, T.F., Fleming,
T.R., Henke, M., Bourhis, J., Rosenthal, D.I., Junor, E., Cmelak, A., Sheehan, F., Pulliam, J.,
Devitt-Risse, P., Fuchs, H., Chambers, M., O'Sullivan, B., Ang, K.K.: A multinational,
randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral
mucositis in patients receiving radiotherapy for head-and-neck malignancy. Int J Radiat Oncol
Biol Phys, 58:674-581, 2004
Henke, M., Laszig, R., Rübe, C., Schäfer, U., Haase, K-D, Schilcher, B., Mose, S., Beer, K.,
Burger, U., Dougherty, C., Frommhold H.: Erythropoietin to treat head and neck cancer
patients with anaemia: randomised, double-blind, placebo-controlled trial. Lancet, 362:12551260, 2003
Momm, F., Weißenberger, C., Bartelt, S., Henke, M: Moist skin care can diminish acute
radiaton-induced skin toxicity. Strahlenther Onkol, 179:708-712, 2003
Pajonk, F, Weissenberger, C., Witucki, G., Henke, M: Vitiligo at sites of irradiation in a patient
with Hodgkin´s disease. Strahlenther Onkol, 178:159-162, 2002
Momm, F., Bechtold, C., Rudat, V., Strnad, V., Tsekos, A., Fischer. K,, Henke, M.: Alteration of
radiation-induced hematotoxicity by amifostine. Int J Radiat Oncol Biol Phys, 51: 947-951,
2001
Schumacher, T., Brink, I., Mix, M., Reinhardt, M., Herget, G., Digel, W., Henke, M., Moser, E.,
Nitzsche, E.: FDG-PET imaging for the staging and follow-up of small cell lung cancer. Eur J
Nucl Med, 28:483-488, 2001
Pajonk, F., Schlessmann, S., Guttenberger, R., Henke, M.: Epithelial cells in the peripheral blood
Michael Henke CV
8
of patients with cancer of the head and neck: incidence, detection and possible clinical
significance. Radiother Oncol, 59:213-217, 2001
Brizel, D.M., Wasserman, T.H., Henke, M., Strnad, V., Rudat, V., Monnier, A., Eschwege, F.,
Zhang, J., Russell, L., Oster, W., Sauer, R.: Phase III randomized trial of amifostine as a
radioprotector in head and neck cancer. J Clin Oncol, 18, 3339-3345, 2000
Rudat, V., Meyer, J., Momm, F., Bendel, M., Henke, M., Strnad, V., Grotz, K., Schulte, A.:
Protective effect of amifostine on dental health after radiotherapy of the head and neck. Int J
Radiat Oncol Biol Phys, 48, 1339-1343, 2000
Henke, M., Bechtold, C., Momm, F., Dörr, W., Guttenberger, R.: Blood Hemoglobin Level May
Affect Radiosensitivity – Preliminary Results on Acutely Reacting Normal Tissues. Int J
Radiat Oncol Biol Phys, 48, 339-345, 2000
Momm, F., Bechtold, C., Fischer, K., Tsekos, A., Henke, M.: Alteration of radiation-induced
hematotoxicity by amifostine. Strahlenther Onkologie 175, 2-5, 1999
Henke, M., Guttenberger, R., Barke, A., Pajonk, F., Pötter, R., Frommhold, H.: Erythropoietin
for patients undergoing radiotherapy: a pilot study. Radiotherapy Oncology, 50, 185-190, 1999
Frommhold, H., Guttenberger, R., Henke, M.: The impact of blood hemoglobin content on the
outcome of radiotherapy: The Freiburg experience. Strahlenther Onkologie, 174, 31-34, 1998
Jonas, D., Lubbert, M., Kawasaki, E.S., Henke, M., Bross, K.J., Mertelsmann, R., Herrmann, F:
Clonal analysis of bcr-abl rearrangement in T lymphocytes from patients with chronic
myelogenous leukemia. Blood, 79, 1017-1023, 1992
Freund, M., Diedrich, H., Ganser, A., Gramatzki, M., Heil, G., Heyll, A., Henke, M.,
Hiddemann, W., Haas, R., Kuse, R., Koch, P., Link, H., Maschmeyer, G., Planker, M.,
Queißer, W., Schadeck-Gressel, C., Schmitz, N., vonVerschuer, U., Wilhelm, S., Thiel, E.,
Hölzer, D.: Treatment of relapsed or refractory adult acute lymphocytic leukemia. Cancer, 69,
709-716, 1992
Glatt, E., Henke, M., Sigmund, G., Costabel, U.: Zyklophosphamid- induzierte Pneumonitis.
Fortschr Röntgenstr, 148, 545-549, 1988
Hecht, Th., Henke, M., Schempp, W., Bross, K.J., Löhr, G.W.: Acute lymphoblastic leukemia in
adult identical twins. Blut 56:261-264, 1988
Henke, M., Santos, S., Winberg, C.D., Shively, J.E.: A monoclonal antibody to the heavy chain
of human IgM with a particular reaction pattern in human B-cell malignancies. Blut, 55,
173-179, 1987
Henke, M., Engler, H., Engelhardt, R., Löhr, G.W.: Successful therapy of sarcoidosis-associated
thrombocytopenia refractory to corticosteroids by a single course of human gammaglobulins.
Klin Wochenschr, 64, 1209-1211, 1986
Münsch, H., Hecht, Th., Winkler, K.J., Gaidulis, L., Henke, M., Blume, K.G.: A monoclonal
antibody to hemoglobin F. Blut, 49, 203-211, 1984
Henke, M., Yonemoto, L.M., Lazar, G.M., Gaidulis, L., Hecht, Th., Santos, S., Blume, K.G.:
Visual detection of granulocyte surface antigens using the avidin-biotin complex. J Histochem
Cytochem, 32, 712-716, 1984
Lazar, G.M., Gaidulis, L., Henke, M., Blume, K.G.: A sensitive screening method of detecting
anti-granulocyte antibodies employing radiolabelled staphylococcal protein A. J Imm Meth, 68,
1-9, 1984
Spruce, W.E., Forman, S.J., Krance, R.A., Farbstein, M.J., Wolf, J.L., Scott, E.P., Nademanee,
Michael Henke CV
9
A.P., Fahey, J.L., Henke, M., Blume, K.G.: Outcome of bone marrow transplantation patients
with extramedullary involvement of acute leukemia. Blut, 48, 75-79, 1983
Metz, J., Amschler, A., Henke, M.: Degos’sche Erkrankung (malignant atrophic papulosis).
Hautarzt, 31: 108-10, 1980
Henke, M., Metz, J.: Degos'sche Erkrankung - Gefäßbefunde einer seltenen Endangiopathie.
Med Welt, 31, 1052-1055, 1980
LETTERS
Henke, M., Laszig, R., Frommhold H.: Erythropoietin to treat anaemia in patients with head and
neck cancer. Lancet, 363:81-82, 2004
Henke, M., Pajonk, F.: Erythropoietin to treat anaemia in patients with head and neck cancer.
Lancet, 363:993, 2004
Frommhold, H., Henke, M.: Adjuvante Therapie bei kolorektalen Carcinomen. Dtsch Med
Wschr, 120:777-779, 1995
REVIEWS
Henke, M.: Clinical trials using rhEPO in radiation oncology. In Nowrousian MR (ed):
Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology. Scientific and Clinical
Aspects of Anemia in Cancer. Springer-Verlag Wien, New York; pp:301-312, 2002
Henke, M., Pajonk, F.: Experimentelle Therapieansätze. In Böttcher HD, SeifertV, Henke M,
Mose St (eds): Klinik der hirneigenen Tumoren und Metastasen. Grundlagen, Diagnostik,
Therapie. W. Zuckschwerdt Verlag GmbH, München, Wien, New York; pp:170-177, 2002
Henke, M.: Correction of cancer anemia - impact on disease course, prognosis and treatment
efficacy, particularly for patients undergoing radiotherapy. Onkologie, 24:450-454, 2001
Henke, M.: Biomodulation der Strahlenreaktion. In Böttcher HD, Kaufmann R, Henke M (eds):
Klinik des Rezidiv-Tumors im Kopf-Hals-Bereich. Grundlagen, Diagnostik, Therapie. W.
Zuckschwerdt Verlag GmbH, München, Wien, New York; pp:105-117, 2000
Henke, M.: Achievements with recombinant erythropoietin in radiotherapy. In Boiron M, Marty
M (eds): Eurocancer 2000. John Libbey Eurotext, Paris; pp:57-58, 2000
Henke, M., Guttenberger, R.: Erythropoietin in radiation oncology - A review. 1st international
conference, Freiburg, June 11-12. 1999. Oncology, 58, 175-182, 2000
Henke, M., Momm, F., Guttenberger, R.: Erythropoietin for patients undergoing radiotherapy.
The Freiburg experience. in Vaupel P, Kelleher DK (eds). Tumor Hypoxia. Pathophysiology,
Clinical Significance and Therapeutic Perspectives. Stuttgart: Wissenschaftliche
Verlagsgesellschaft; pp 91-97, 1999
Eschwege, F., Sauer, R., Wannenmacher, M., Wassermann, T., Henke, M., Monier, A., Brizel,
D.: Étude randomisée de phase III comparant irradiation avec ou sans amifostine chez des
patients porteurs de tumeurs de la tête et du cou. In Lubionsky B: Cancers des voies aérodigestives supérieurs. L’avant et l’après traitement. Quel bilan? Quel suivi? EDK, Paris;
pp:128-130, 1999
Guttenberger, R., Henke, M., Frommhold, H.: Erythropoietin – a radiosensitizer? in: H.D.
Kogelnik, F. Sedelmayer: Progress in Radio-Oncology VI. Monduzzi Editore, Bologna;
pp:223-226, 1998
Michael Henke CV
10
Henke, M., Pajonk, F., Barke, A.: Strahlenbehandlung von Knochenmetastasen
Entscheidungsbasis: Wünsche des Patienten an die Lebensqualität. Krankenhaus Arzt, 70:443445, 1997
Henke, M., Bross, K.J.: Haematologie. in Droste C, vonPlanta M (eds): Memorix, Konstanten der
klinischen Medizin, VCH Verlagsgesellschaft mbH Weinheim. pp:207-230 and pp:231-240,
1993
Leder, G.H., Henß, H., Henke, M., Engler, H., Fiebig, H.H., Löhr, G.W., Arnold, H.: Neopterin
in the monitoring of cancer patients treated with a standardized liver- and spleen-extract. in
Kuhlmann J, Wingender (eds): Dose-response relationship of drugs, Zuckschwerdt Verlag
München Bern Wien San Francisco. pp:201-206, 1990
Henke, M., Hecht, Th., Löhr, G.W.: Myelopoietic reconstitution following autologous bone
marrow transplantation. in Büchner T, Schellong G, Hiddemann W, Ritter J (eds):
Haematology and Blood Transfusion Vol. 33 Acute Leukemias II, Springer Verlag Berlin
Heidelberg. pp:702-706, 1990
Freund, M., DeBoben, M., Diedrich, H., Ganser, A., Heil, G., Heyll, A., Henke, M., Hiddemann,
W., Hölzer, D., Koch, P., Küchler, R., Link, H., Maschmeyer, G., Planker, M., Renner, D.,
Schmitz, N.: Treatment of relapsed acute lymphocytic leukemia in adults. in Büchner T,
Schellong G, Hiddemann W, Ritter J (eds): Haematology and Blood Transfusion Vol. 33 Acute
Leukemias II, Springer Verlag Berlin Heidelberg. pp:432-436, 1990
Link, H., Freund, M., Diedrich, H., Wilke, H., Austein, J., Henke, M., Wandt, H.,
Fackler-Schwalbe, E., Schlimock, G., Hoffmann, R., Calavrezos, A., Poliwoda, H.:
Mitoxantrone, cytosine-arabinoside and VP-16 (MAV) in 36 patients with relapsed and
refractory acute myeloid leukemia. in Büchner T, Schellong G, Hiddemann W, Ritter J (eds):
Haematology and Blood Transfusion Vol. 33 Acute Leukemias II, Springer Verlag Berlin
Heidelberg. pp:322-325, 1990
Ehninger, G., Fackler-Schwalbe, E., Freund, M., Heil, G., Henke, M., Hölzer, D., Hoffmann, R.,
Kurrle, E., Link, H., Lösch, A., Mitrou, P.S., Queißer, W., Schlimok, G., Wandt, H.
(Süddeutsche Hämoblastosegruppe): Combination of mitoxantrone and etoposid in patients
aged over 60 years with untreated acute myelogenous leukemia. in Büchner T, Schellong G,
Hiddemann W, Ritter J (eds): Haematology and Blood Transfusion Vol. 33 Acute Leukemias
II, Springer Verlag Berlin Heidelberg. pp:316-317, 1990
Hecht, Th., Arnold, H., Henke, M.,: Spättoxizität nach der Therapie maligner Hodentumoren. in:
Schmoll HJ, Weißbach L (eds): Therapie von Hodentumoren, Springer Verlag Heidelberg.
pp:510-516, 1988
Löhr, G.W., Hecht, Th., Henke, M.,: Therapiekonzepte zur Behandlung von Patienten mit akuten
Leukämien. In Hilgarth M und Mönig-Schuth M (eds): Festschrift. Konstanzer Verlagsanstalt.
pp:277-293, 1988
Blume, K.G., Forman, S.J., Krance, R.A., Henke, M., Findley, D.O., Hill, R.A.: Bone marrow
transplantation for acute leukemia. in: Neth R, Gallo RC, Greaves MF, Janka G (eds): Modern
trends in human leukemia VI, Springer Verlag Berlin-Heidelberg, pp:39-41, 1985
Henke, M., Yonemoto, L.M., Lazar, G.M., Blume, K.G.: Immunoenzymatic detection of blood
cell surface antigens using the avidin-biotin complex. in: Avrameas S, Druet A, Masseyeff R,
Feldmann G (eds): Immunoenzymatic techniques, Elsevier Science Publ, Amsterdam, pp:41-44,
1984
Michael Henke CV
ABSTRACTS
More than 120 published
11